They followed up with a second trial:
September 11, 2026 at 7:00 PM
They followed up with a second trial:
Simmaron Research, 76 people with ME/CFS.
After 90 days of low-dose rapamycin, fatigue and PEM improved as IMPDH2 activity fell, oxidative purines dropped, and mitochondrial reserve recovered.
No placebo group tempers the result.
link.springer.com/article/10.1...
After 90 days of low-dose rapamycin, fatigue and PEM improved as IMPDH2 activity fell, oxidative purines dropped, and mitochondrial reserve recovered.
No placebo group tempers the result.
link.springer.com/article/10.1...
Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in...
Background and rationale In our ongoing phase II observational pilot trial, the compounded formulation of low-dose rapamycin significantly reduced fatigue-related clinical symptoms in ME/CFS subjects....
link.springer.com
July 12, 2026 at 11:36 PM
Simmaron Research, 76 people with ME/CFS.
After 90 days of low-dose rapamycin, fatigue and PEM improved as IMPDH2 activity fell, oxidative purines dropped, and mitochondrial reserve recovered.
No placebo group tempers the result.
link.springer.com/article/10.1...
After 90 days of low-dose rapamycin, fatigue and PEM improved as IMPDH2 activity fell, oxidative purines dropped, and mitochondrial reserve recovered.
No placebo group tempers the result.
link.springer.com/article/10.1...
Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP
Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP
A cytoplasmic interaction between EZH2 and IMPDH2 drives GTP synthesis to promote cancer progression independently of EZH2’s methyltransferase activity. This newly discovered oncogenic mechanism, observed across multiple cancer types, including melanoma, can be disrupted pharmacologically, highlighting a novel vulnerability for therapeutic targeting.
dlvr.it
July 7, 2026 at 3:19 PM
Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP
A paper using RRID:AB_10852703 from @thermofishersci.bsky.social was just published in Molecular Cell. RRIDs improve reproducibility in scientific research. #ReproducibleResearch #OpenResearch #accelerateopenscience
Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP
Read the full paper: Cytosolic EZH2-IMPDH2 complexes regulate melanoma progression and metastasis via GTP
doi.org
July 6, 2026 at 7:00 AM
A paper using RRID:AB_10852703 from @thermofishersci.bsky.social was just published in Molecular Cell. RRIDs improve reproducibility in scientific research. #ReproducibleResearch #OpenResearch #accelerateopenscience
A Metabolic Weakness in Brain Metastases — And a Drug That Hits It Without Destroying the Immune System 🔬
https://1ban.news/impdh2-brain-metastases-inhibitor/
https://1ban.news/impdh2-brain-metastases-inhibitor/
A Metabolic Weakness in Brain Metastases — And a Drug That Hits It Without Destroying the Immune System - 1ban.news
Brain metastases are among the most devastating complications in oncology. When cancer spreads to the brain, the prognosis is grim: roughly 90% of patients die within 12 months. Current treatments, surgery, radiation, and stereotactic radiosurgery, are palliative, not curative. No drug is approved to prevent brain metastases from forming in the first place. A new
1ban.news
June 30, 2026 at 12:35 AM
A Metabolic Weakness in Brain Metastases — And a Drug That Hits It Without Destroying the Immune System 🔬
https://1ban.news/impdh2-brain-metastases-inhibitor/
https://1ban.news/impdh2-brain-metastases-inhibitor/
HSPA6 maintains IMPDH2 phosphorylation to regulate GTP synthesis for driving radioresistance of glioblastoma stem cells
HSPA6 maintains IMPDH2 phosphorylation to regulate GTP synthesis for driving radioresistance of glioblastoma stem cells
Yang et al. show that irradiation-induced HSPA6 recruits ROCK2 and maintains tetramer formation of IMPDH2, a key rate-limiting enzyme in purine biosynthesis, which in turn promotes GTP synthesis and reduces DNA damage to drive radioresistance of GSCs. Targeting HSPA6 and IMPDH2 may improve the efficacy of radiotherapy for GBM.
dlvr.it
June 19, 2026 at 11:23 PM
HSPA6 maintains IMPDH2 phosphorylation to regulate GTP synthesis for driving radioresistance of glioblastoma stem cells
Selective IMPDH2-targeting drug candidates could help stop cancer from spreading to the brain before tumors form there. The target is not abundant in healthy tissue, suggesting fewer major side effects. doi.org/hb782x
Targeting enzyme could block cancer spread to brain with fewer side effects
A new study has identified a more precise and effective way to prevent cancer from spreading to the brain. The paper, published in the Proceedings of the National Academy of Sciences, details the development of novel drug candidates that target a key enzyme implicated in the spread of lung, breast, skin and other cancers to the brain.
medicalxpress.com
June 19, 2026 at 5:00 PM
Selective IMPDH2-targeting drug candidates could help stop cancer from spreading to the brain before tumors form there. The target is not abundant in healthy tissue, suggesting fewer major side effects. doi.org/hb782x
@proteintech.bsky.social's resource, RRID:AB_2120122, was just reported to be used in the paper. RRIDs improve reproducibility in scientific research. #ReproducibleResearch #BetterScience #OpenResearch
HSPA6 maintains IMPDH2 phosphorylation to regulate GTP synthesis for driving radioresistance of glioblastoma stem cells
Read the full paper: HSPA6 maintains IMPDH2 phosphorylation to regulate GTP synthesis for driving radioresistance of glioblastoma stem cells
doi.org
June 5, 2026 at 7:00 AM
@proteintech.bsky.social's resource, RRID:AB_2120122, was just reported to be used in the paper. RRIDs improve reproducibility in scientific research. #ReproducibleResearch #BetterScience #OpenResearch
The authors included RRIDs in their in Proceedings of the National Academy of Sciences paper! We value the author's support of reproducibility. #reproducibility #ReproducibleResearch #accelerateopenscience
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somite organization
Read the full paper: An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somite organization
doi.org
March 25, 2026 at 7:03 AM
The authors included RRIDs in their in Proceedings of the National Academy of Sciences paper! We value the author's support of reproducibility. #reproducibility #ReproducibleResearch #accelerateopenscience
The authors included RRIDs in their in Cancer Letters paper! RRIDs improve reproducibility in scientific research. #BetterScience #methodsmatter #OpenScience
tRF-1432 orchestrates RBMS1–IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer
Read the full paper: tRF-1432 orchestrates RBMS1–IMPDH2 regulatory control to drive purine-dependent chemoresistance in breast cancer
doi.org
March 7, 2026 at 8:02 AM
The authors included RRIDs in their in Cancer Letters paper! RRIDs improve reproducibility in scientific research. #BetterScience #methodsmatter #OpenScience
The Legionella phosphocholinase AnkX modulates IMPDH2 regulation and cytoophidia dynamics https://www.biorxiv.org/content/10.64898/2026.01.26.701698v1
February 10, 2026 at 5:19 PM
The Legionella phosphocholinase AnkX modulates IMPDH2 regulation and cytoophidia dynamics https://www.biorxiv.org/content/10.64898/2026.01.26.701698v1
The Legionella phosphocholinase AnkX modulates IMPDH2 regulation and cytoophidia dynamics https://www.biorxiv.org/content/10.64898/2026.01.26.701698v1
February 10, 2026 at 5:19 PM
The Legionella phosphocholinase AnkX modulates IMPDH2 regulation and cytoophidia dynamics https://www.biorxiv.org/content/10.64898/2026.01.26.701698v1
Feed: "BIOENGINEER.ORG"
By: Bioengineer on Saturday, February 7, 2026
By: Bioengineer on Saturday, February 7, 2026
Newly Discovered Limonoid DHL-11 from Munronia henryi Targets IMPDH2 to Combat Triple-Negative Breast Cancer
A groundbreaking study recently published in the prestigious journal Acta Pharmaceutica Sinica B has unveiled a promising new therapeutic candidate, DHL-11, a novel prieurianin-type limonoid isolated
bioengineer.org
February 7, 2026 at 4:35 AM
Feed: "BIOENGINEER.ORG"
By: Bioengineer on Saturday, February 7, 2026
By: Bioengineer on Saturday, February 7, 2026
The inosine-5′-monophosphate dehydrogenase-2 (#IMPDH2) enzyme is highly expressed in peripheral blood mononuclear cells and CD4-positive T cells from patients with #MyastheniaGravis (MG). Study in Clinical Immunology.
Read more: https://bit.ly/44BygsA
#RareDisease #MedSky
Read more: https://bit.ly/44BygsA
#RareDisease #MedSky
Study Sheds Light on Pathogenesis of Myasthenia Gravis
A team of researchers worked to shed light on the mechanism of CD4-positive T-cell regulation by IMPDH2 in MG.
bit.ly
December 5, 2025 at 6:53 PM
The inosine-5′-monophosphate dehydrogenase-2 (#IMPDH2) enzyme is highly expressed in peripheral blood mononuclear cells and CD4-positive T cells from patients with #MyastheniaGravis (MG). Study in Clinical Immunology.
Read more: https://bit.ly/44BygsA
#RareDisease #MedSky
Read more: https://bit.ly/44BygsA
#RareDisease #MedSky
A Novel Allosteric Inhibitor Targeting IMPDH2 at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma https://www.biorxiv.org/content/10.1101/2025.08.19.667179v1
August 24, 2025 at 5:48 AM
A Novel Allosteric Inhibitor Targeting IMPDH2 at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma https://www.biorxiv.org/content/10.1101/2025.08.19.667179v1
A Novel Allosteric Inhibitor Targeting IMPDH2 at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma https://www.biorxiv.org/content/10.1101/2025.08.19.667179v1
August 24, 2025 at 5:48 AM
A Novel Allosteric Inhibitor Targeting IMPDH2 at Y233 Overcomes Resistance to Tyrosine Kinase Inhibitors in Lymphoma https://www.biorxiv.org/content/10.1101/2025.08.19.667179v1
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somitogenesis pubmed.ncbi.nlm.nih.gov/40654686/ #cryoem
July 15, 2025 at 10:55 PM
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somitogenesis pubmed.ncbi.nlm.nih.gov/40654686/ #cryoem
Look at this amount of work that has gone into the analysis of these beautiful (yes, we are biased) images of rods and rings. Now you can automatically classify these structures which is rather tedious to do manually. 🔬📷🖼️💻📄 bmcbiol.biomedcentral.com/articles/10....
Domain-specific AI segmentation of IMPDH2 rod/ring structures in mouse embryonic stem cells - BMC Biology
Background Inosine monophosphate dehydrogenase 2 (IMPDH2) is an enzyme that catalyses the rate-limiting step of guanine nucleotides. In mouse embryonic stem cells (ESCs), IMPDH2 forms large multi-prot...
bmcbiol.biomedcentral.com
May 13, 2025 at 3:46 PM
Look at this amount of work that has gone into the analysis of these beautiful (yes, we are biased) images of rods and rings. Now you can automatically classify these structures which is rather tedious to do manually. 🔬📷🖼️💻📄 bmcbiol.biomedcentral.com/articles/10....
New preprint from the Kollman/Wills collab! My colleague Audrey O'Neill and friends demonstrate the effects of an IMPDH2 mutant associated with neurodevelopmental disorders on development using a Xenopus model. Beautiful electron and light microscopy included!
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somitogenesis
IMP dehydrogenase (IMPDH) controls a key regulatory node in purine biosynthesis. Gain-of-function mutations in human IMPDH2 are associated with neurodevelopmental disorders and neuromuscular symptoms ...
www.biorxiv.org
May 12, 2025 at 5:11 PM
New preprint from the Kollman/Wills collab! My colleague Audrey O'Neill and friends demonstrate the effects of an IMPDH2 mutant associated with neurodevelopmental disorders on development using a Xenopus model. Beautiful electron and light microscopy included!
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Our new paper just arrived! Fun collaborative effort led by Sam Ball and Meagan Hennessy to develop an AI tool to segment and classify #IMPDH2 rod-rings in mouse ESCs doi.org/10.1186/s129...
Domain-specific AI segmentation of IMPDH2 rod/ring structures in mouse embryonic stem cells - BMC Biology
Background Inosine monophosphate dehydrogenase 2 (IMPDH2) is an enzyme that catalyses the rate-limiting step of guanine nucleotides. In mouse embryonic stem cells (ESCs), IMPDH2 forms large multi-prot...
doi.org
May 12, 2025 at 7:29 AM
Our new paper just arrived! Fun collaborative effort led by Sam Ball and Meagan Hennessy to develop an AI tool to segment and classify #IMPDH2 rod-rings in mouse ESCs doi.org/10.1186/s129...
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somitogenesis www.biorxiv.org/content/10.1101/2025.05.09.652712v1 #cryoem
May 12, 2025 at 7:10 AM
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somitogenesis www.biorxiv.org/content/10.1101/2025.05.09.652712v1 #cryoem
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somitogenesis https://www.biorxiv.org/content/10.1101/2025.05.09.652712v1
May 11, 2025 at 7:46 AM
An IMPDH2 variant associated with neurodevelopmental disorder disrupts purine biosynthesis and somitogenesis https://www.biorxiv.org/content/10.1101/2025.05.09.652712v1